This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorLTZ Therapeutics, Inc.

About this trial

This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Advanced /metastatic colorectal tumors that have failed standard treatments

Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1

Adequate organ function based on laboratory testing

Disqualifiers

Active infection with hepatitis B or C

Uncontrolled CNS metastases

Active autoimmune disease

Clinically significant cardiovascular disease not adequately controlled with medication or impaired function

Trial design

Design model

Sequential

Treatments tested in this trial

  • LTZ-232

    Drug

    LTZ-232 will be administered intravenously every two weeks for up to 24 months unless treatment discontinuation criteria are met.

Treatment groups

152 Participants
are divided into 3 treatment groups
Group A: Dose Escalation in metastatic colorectal cancerExperimental treatment 1 intervention
Group B: Safety/PK/Pharmacodynamic CohortsExperimental treatment 1 intervention
Group C: Dose Expansion in metastatic colorectal cancer and other solid tumor typesExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Characterize the Safety and Tolerability of LTZ-232 in metastatic colorectal cancer and other solid tumors using the incidence, severity, and type of adverse events according to CTCAE v5.0.

To determine the incidence, severity, and type of adverse events according to NCI and CTCAE v5.0 and assessment of protocol defined dose limiting toxicity criteria.

Time frame
Up to 24 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.